Close Menu

Centogene

Revenues have begun to recover in Q3, driven by a ramp in SARS-CoV-2 testing, and the firm now expects full-year 2020 revenues to exceed its prior guidance.

The firms will combine real-life data sets in rare diseases with expertise in big data, artificial intelligence, and computational algorithms.

The offering consists of 2 million common shares offered by the company and 1.5 million common shares offered by selling shareholders at a price of $14 per share.

Earlier this month Centogene said that previously acquired laboratory space in Hamburg is now exclusively performing SARS-CoV-2 testing.

The Rostock, Germany-based company reported €12.1 million ($13.6 million) in revenues, missing the average analyst estimate of $14.7 million.

The company, headquartered in Rostock, Germany, reported €15.2 million ($16.4 million) in revenues for Q4, with growth driven by its pharmaceutical business.

Clinical sequencing consumables revenues grew 20 percent year over year and accounted for just over 40 percent of total consumables shipments in 2019.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.